Time to look Beyond Compulsory Licenses? A Glimpse at the Ribociclib Case
SpicyIP
OCTOBER 31, 2023
She is keenly interested in Intellectual Property Law, Technology Law, and Corporate Law ]. Image from here Recently, the Print reported that Novartis and Eli Lilly have voiced their opposition to the idea of compulsory licensing (“ CL ”) for breast cancer medications, Ribociclib and Abemaciclib. – An estimated 3.2
72 
Let's personalize your content